EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a ...

Cancer immunotherapy is a strategy that turns the patient’s own immune cells into a “search-and-destroy” force that attacks the tumor’s cells. The “search” immune cells are the dendritic cells, which ...

Researchers at Kobe University discovered an entirely new and unexpected mechanism by which the immune system can get rid of cells lacking molecules that identify them as part of the self in mice. The ...

Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). Survival ...

A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk ...

Dendritic cells alter the chemokine gradient they follow to direct themselves to the lymph nodes. An immune response is an impressive feat of collective migration involving many cell types and ...

A new study suggest that using CXCL9 and CXCL10-producing dendritic cells alongside immunotherapy can be a promising strategy to overcome treatment resistance and improve clinical outcomes for ...

Immunotherapy has emerged as a promising alternative in cancer treatment to traditional chemotherapy, offering gentler treatment options with fewer side effects for cancer patients. However, ...

BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines help ...

Cancer immunotherapy transforms a patient’s immune cells into a “search‑and‑destroy” force against tumors. But many cancers learn to camouflage themselves from dendritic cells—the immune system’s ...